Axsome Therapeutics, INC. (AXSM) — SEC Filings

Overview

Axsome Therapeutics, INC. (AXSM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 31, 2025: Axsome Therapeutics, Inc. filed an 8-K on December 31, 2025, reporting on other events and financial statements. The filing details the company's corporate information, including its principal executive offices at One World Trade Center, New York, NY, and its fiscal year end of December 31.

Sentiment Summary

Across 41 filings, the sentiment breakdown is: 1 bullish, 39 neutral, 1 mixed. The dominant filing sentiment for Axsome Therapeutics, INC. is neutral.

Filing Type Overview

Axsome Therapeutics, INC. (AXSM) has filed 1 4, 26 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (41)

• 4 Filing — 4 · Apr 24, 2026
• Axsome Therapeutics Files 8-K — 8-K · Dec 31, 2025 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on December 31, 2025, reporting on other events and financial statements. The filing details the company's corporate info
• Axsome's Revenue Soars 66% on New Drug Launch, Losses Narrow — 10-Q · Nov 3, 2025 Risk: medium
  Axsome Therapeutics, Inc. (AXSM) reported a significant increase in total revenues for the nine months ended September 30, 2025, reaching $442.497 million, up f
• Axsome Therapeutics Files 8-K — 8-K · Aug 20, 2025 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting other events and financial statements as of August 19, 2025. The filing does not detail spe
• Axsome's Revenue Soars 75% on Auvelity, Sunosi Sales; Net Loss Narrows — 10-Q · Aug 4, 2025 Risk: medium
  Axsome Therapeutics, Inc. reported a significant increase in product revenue for the three months ended June 30, 2025, reaching $105.2 million, up from $60.1 mi
• Axsome Therapeutics Files 8-K — 8-K · Jun 10, 2025 Risk: low
  On June 10, 2025, Axsome Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicatin
• Axsome Therapeutics Files 8-K — 8-K · Jun 9, 2025 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on June 9, 2025, reporting other events and financial statements. The filing does not contain specific details on new eve
• Axsome Therapeutics Files 8-K — 8-K · May 27, 2025 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on May 27, 2025, reporting other events and financial statements. The filing does not contain specific details on new eve
• Axsome Therapeutics Files 8-K with Key Agreements and Sales — 8-K · May 13, 2025 Risk: medium
  On May 8, 2025, Axsome Therapeutics, Inc. entered into a material definitive agreement and simultaneously terminated another. The company also created a direct
• Axsome Therapeutics Files Q1 2025 10-Q — 10-Q · May 5, 2025 Risk: medium
  Axsome Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company's financial statements reflect its ongoing operations and financial p
• Axsome Therapeutics DEF 14A: Executive Compensation Details — DEF 14A · Apr 25, 2025 Risk: low
  Axsome Therapeutics, Inc. filed a DEF 14A on April 25, 2025, detailing executive compensation and stock awards. The filing includes information on the fair valu
• Axsome Therapeutics Files 8-K — 8-K · Apr 1, 2025 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on April 1, 2025, reporting other events and financial statements. The filing does not contain specific financial figures
• Axsome Therapeutics Files 8-K Report — 8-K · Mar 25, 2025 Risk: low
  On March 25, 2025, Axsome Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicati
• Axsome Therapeutics Files 8-K — 8-K · Mar 5, 2025 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on March 5, 2025, to report other events and financial statements. The filing does not contain specific details about the
• Axsome Therapeutics Files 8-K — 8-K · Mar 3, 2025 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on March 3, 2025, to report other events and financial statements. The filing does not contain specific financial figures
• 10-K Filing — 10-K · Feb 18, 2025
• Axsome Therapeutics Files 8-K Report — 8-K · Feb 10, 2025 Risk: low
  On February 10, 2025, Axsome Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indic
• Axsome Therapeutics Files 8-K Report — 8-K · Jan 31, 2025 Risk: low
  On January 30, 2025, Axsome Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indica
• Axsome Therapeutics Files 8-K on Financials and Events — 8-K · Jan 13, 2025 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition, as well as other events. The filing
• Axsome Therapeutics Files 8-K — 8-K · Dec 30, 2024 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on December 30, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain speci
• Axsome Therapeutics Files 8-K — 8-K · Nov 26, 2024 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on November 26, 2024, to report other events and financial statements. The filing does not contain specific details about
• Axsome Therapeutics Q3 2024 Update — 10-Q · Nov 12, 2024 Risk: medium
  Axsome Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and business operations, in
• Axsome Therapeutics Enters Material Definitive Agreement — 8-K · Oct 1, 2024 Risk: medium
  On September 30, 2024, Axsome Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details on the agreement or
• Axsome Therapeutics Files 8-K — 8-K · Sep 4, 2024 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on September 4, 2024, reporting other events and financial statements. The filing details the company's principal executi
• Axsome Therapeutics Files 8-K — 8-K · Aug 21, 2024 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on August 21, 2024, reporting other events and financial statements/exhibits. The filing details the company's principal
• Axsome Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 5, 2024 Risk: medium
  Axsome Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance, including details on employee s
• Axsome Therapeutics Files 8-K for Shareholder Votes & Exhibits — 8-K · Jun 11, 2024 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on June 7, 2024, to report on matters submitted to a vote of security holders and to file financial statements and exhibi
• Axsome Therapeutics Files 8-K — 8-K · Jun 5, 2024 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on June 5, 2024, to report other events and financial statements. The filing does not contain specific details about new
• Axsome Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 6, 2024 Risk: medium
  Axsome Therapeutics, Inc. (AXSM) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Axsome Therapeutics, Inc. filed a 10-Q report for the period endin
• Axsome Therapeutics, Inc. Files Definitive Proxy Statement — DEF 14A · Apr 26, 2024 Risk: low
  Axsome Therapeutics, Inc. (AXSM) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Filing is a Definitive Proxy Statement (DEF 14A) filed on Apr
• Axsome Therapeutics Files 8-K — 8-K · Apr 1, 2024 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on April 1, 2024, reporting an event that occurred on March 28, 2024. The filing primarily concerns financial statements
• Axsome Therapeutics Files 8-K — 8-K · Mar 25, 2024 Risk: low
  On March 25, 2024, Axsome Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update r
• Axsome Therapeutics Files 8-K Report — 8-K · Mar 19, 2024 Risk: low
  On March 19, 2024, Axsome Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of other events and the inclusion of financial s
• Axsome Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 23, 2024 Risk: medium
  Axsome Therapeutics, Inc. (AXSM) filed a Annual Report (10-K) with the SEC on February 23, 2024. Axsome Therapeutics, Inc. filed its 2023 Form 10-K on February
• Axsome Therapeutics Files 8-K on Financial Condition — 8-K · Feb 20, 2024 Risk: low
  Axsome Therapeutics, Inc. filed an 8-K on February 20, 2024, to report on its results of operations and financial condition. The filing, under SEC File Number 0
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• BlackRock Amends Axsome Therapeutics Stake, Signals Continued Confidence — SC 13G/A · Jan 26, 2024
  BlackRock, Inc. filed an amended SC 13G/A on January 26, 2024, disclosing its ownership in Axsome Therapeutics, Inc. as of December 31, 2023. This filing, an Am
• Axsome Therapeutics Files 8-K for 'Other Events' & Financial Exhibits — 8-K · Jan 8, 2024
  Axsome Therapeutics, Inc. filed an 8-K on January 8, 2024, to report an "Other Event" and provide "Financial Statements and Exhibits." This filing, under SEC Fi
• Axsome Therapeutics Files 8-K on Financial Condition & Other Events — 8-K · Jan 4, 2024
  Axsome Therapeutics, Inc. filed an 8-K on January 4, 2024, to report on "Results of Operations and Financial Condition" and "Other Events." This filing indicate

Risk Profile

Risk Assessment: Of AXSM's 33 recent filings, 0 were flagged as high-risk, 9 as medium-risk, and 24 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Axsome Therapeutics, INC.'s most recent 10-Q filing (Nov 3, 2025):

• Revenue: $442.497M
• Net Income: -$154.615M
• EPS: Not Disclosed
• Debt-to-Equity: Not Disclosed
• Cash Position: $325.272M
• Operating Margin: Not Disclosed
• Total Assets: Not Disclosed
• Total Debt: Not Disclosed

Key Executives

• Mark Jacobson
• Nick Pizzie

Industry Context

Axsome Therapeutics operates within the highly competitive biopharmaceutical sector, specifically focusing on Central Nervous System (CNS) disorders. This market is characterized by significant unmet medical needs and substantial R&D investment. Key trends include the development of novel therapies for conditions like depression, sleep disorders, and migraines, alongside increasing regulatory scrutiny and pricing pressures.

Top Tags

8-K (10) · financials (9) · sec-filing (8) · 8-k (8) · filing (5) · corporate-filing (4) · regulatory-filing (4) · Pharmaceuticals (3) · 10-Q (3) · financial-condition (3)

Key Numbers

• Total Revenues (9 months ended Sep 30, 2025): $442.497M — Increased from $266.927M in 2024, a 65.7% increase, driven by product sales.
• Net Loss (9 months ended Sep 30, 2025): $154.615M — Improved from a net loss of $212.304M in 2024, representing a 27.2% reduction.
• Cash and Cash Equivalents (as of Sep 30, 2025): $325.272M — Increased from $315.353M at December 31, 2024, providing liquidity for operations.
• Accumulated Deficit (as of Sep 30, 2025): $1,277.4M — Indicates historical operating losses, despite recent revenue growth.
• Selling, General and Administrative Expenses (9 months ended Sep 30, 2025): $401.302M — Increased from $298.088M in 2024, reflecting significant commercialization investments.
• Common Shares Outstanding (as of Oct 27, 2025): 50,412,640 — Reflects potential dilution from stock issuances.
• Product Revenue (Q2 2025): $105.2M — Increased from $60.1 million in Q2 2024, a 75% increase.
• Total Revenue (Six Months 2025): $198.7M — Increased from $108.9 million in the prior year period.
• Net Loss (Q2 2025): $25.3M — Improved from a net loss of $50.2 million in Q2 2024.
• Net Loss Per Share (Q2 2025): $0.52 — Improved from $1.10 per share in Q2 2024.
• R&D Expense (Q2 2025): $28.7M — Decreased from $35.1 million in Q2 2024.
• G&A Expense (Q2 2025): $70.1M — Increased from $60.3 million in Q2 2024 due to commercialization.
• Blackstone Term Loan Facility: $300.0M — New financing secured in May 2025, with $100.0 million initially drawn.
• Commission File Number: 001-37635 — Axsome Therapeutics' SEC identifier
• IRS Employer Identification No.: 45-4241907 — Axsome Therapeutics' tax identifier

Related Companies

JAZZ · PFE

Frequently Asked Questions